Retrospective Cohort Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jul 24, 2024; 15(7): 840-847
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.840
Impact of hyperthermic intraperitoneal chemotherapy on gastric cancer survival: Peritoneal metastasis and cytology perspectives
Asada Methasate, Thammawat Parakonthun, Thita Intralawan, Chawisa Nampoolsuksan, Jirawat Swangsri
Asada Methasate, Thammawat Parakonthun, Thita Intralawan, Chawisa Nampoolsuksan, Jirawat Swangsri, Minimally Invasive Surgery Unit, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Asada Methasate, Thammawat Parakonthun, Chawisa Nampoolsuksan, Jirawat Swangsri, Upper Gastrointestinal Cancer Center, Siriraj Hospital Mahidol University, Bangkok 10700, Thailand
Author contributions: Methasate A and Parakonthun T were involved in the conception, design, data handling, manuscript drafting and revision, and final approval; Parakonthun T additionally managed the data and assumed corresponding author responsibilities; Intralawan T, Nampoolsuksan C, and Swangsri J conducted the data analysis, participated in manuscript revision, and provided final approval; All authors reviewed and approved the final version.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Siriraj Institutional Review Board (COA No. Si 733/2020).
Informed consent statement: Informed consent was not required for this retrospective cohort study.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: Consent was not obtained for this study, but the presented data are anonymized, and the risk of identification is low. We are committed to promoting transparency and facilitating the advancement of research. Upon reasonable request, data supporting the findings of this study will be made available by the corresponding author.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Thammawat Parakonthun, MD, Associate Professor, Minimally Invasive Surgery Unit, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wang Lang Road, Bangkok 10700, Thailand. thammawat.paa@mahidol.edu
Received: March 12, 2024
Revised: May 11, 2024
Accepted: June 3, 2024
Published online: July 24, 2024
Processing time: 125 Days and 14.9 Hours
Core Tip

Core Tip: This investigation evaluated the survival outcomes of 84 advanced gastric cancer patients from 2013 to 2020. Among them, the hyperthermic intraperitoneal chemotherapy (HIPEC) cohort, characterized by peritoneal nodules, underwent longer surgeries and experienced greater blood loss; however, the rate of complications did not significantly differ among groups. The HIPEC group’s median survival was 20.00 ± 4.89 mo, with 1-year, 2-year, and 3-year survival rates of 73.90%, 28.70%, and 9.60%, respectively. These rates were akin to those of the cytology-positive group. While HIPEC appears to offer a survival benefit, particularly in the short term, the incidence of peritoneal recurrence remains high.